Jianzhou Yan
Biographic Data
| ID | 10030089 |
|---|---|
| NAME | Jianzhou Yan |
| GIVEN NAMES | Jianzhou |
| FAMILY NAME | Yan |
| SIGNATURE | YAN J |
| AFFILIATIONS | China Pharmaceutical University |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines—Taking Oncology Medicines as an Example
The concepts of “essential medicine” and “national medicine policy” were first put forward for the first time at the World Health Assembly in 1975 in an effort to alleviate the problem of medicine unavailability in developing and poor countries. The essential medicine system in China has experienced three development stages since 1979, when the concept of essential medicines was first introduced, to actively respond to the call of the World Healt…
Degarelix vs. leuprorelin for the treatment of prostate cancer in China
Objective: To explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective. Methods: A Markov model, adapted from the one established in Finland was conducted for the cost-effectiveness analysis of degarelix and leuprorelin for Pca treatment. The main data were derived from global phase III clinical trials of degarelix…
No prominent works on this page.
The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines—Taking Oncology Medicines as an Example
The concepts of “essential medicine” and “national medicine policy” were first put forward for the first time at the World Health Assembly in 1975 in an effort to alleviate the problem of medicine unavailability in developing and poor countries. The essential medicine system in China has experienced three development stages since 1979, when the concept of essential medicines was first introduced, to actively respond to the call of the World Healt…
Degarelix vs. leuprorelin for the treatment of prostate cancer in China
Objective: To explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective. Methods: A Markov model, adapted from the one established in Finland was conducted for the cost-effectiveness analysis of degarelix and leuprorelin for Pca treatment. The main data were derived from global phase III clinical trials of degarelix…
Medicine (2 works) · Alternative medicine (1 work) · Cancer (1 work) · Cancer, Lipids, and Metabolism (1 work) · Complementary and Alternative Medicine Studies (1 work) · Computer Science (1 work) · Cost effectiveness (1 work) · Economic and Financial Impacts of Cancer (1 work) · Economics (1 work) · Environmental health (1 work)